BioCentury
ARTICLE | Finance

How Nextech-led round will help Vividion to POC

$82M B round to advance small molecules from proteome-wide drug discovery platform

April 30, 2019 10:08 AM UTC

After identifying three lead programs with its proteome-wide small molecule screening platform, San Diego-based Vividion has raised $82 million in an oversubscribed series B round led by new investor Nextech Invest.

Now flush with over $165 million in cash, Vividion Therapeutics Inc. CEO Diego Miralles said the company will be able to generate clinical proof-of-concept data for at least two programs...